Table 2 Current listed clinical trials on ABT-869
From: ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside
Trial title | Enrollment | Trial design | Last verified | Recruitment | Start date |
|---|---|---|---|---|---|
Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone as First Line Treatment For Metastatic Breast Cancer | 102 | RDBT, MC | April 2009 | Recruiting | March 2008 |
Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC) | 44 | RDBT, MC | March 2009 | Active, not recruiting | August 2007 |
Study of ABT-869 in Combination With Tarceva in Subjects With Solid Tumors | 0 | W | January 2009 | Withdrawn | September 2008 |
Phase 1 Study of ABT-869 in Subjects With Solid Tumors | 24 | Conducted in Japan | March 2009 | Recruiting | September 2008 |
Phase 2 Study of ABT-869 in Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC) | 139 | RUO, MC | March 2009 | Active, not recruiting | August 2007 |
Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 as Second Line Treatment for Advanced Colorectal Cancer | 102 | RUO, MC | April 2009 | Recruiting | August 2008 |
Phase 2 Study of Carboplatin/Paclitaxel in Combination With ABT-869 in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | 80 | RDBT, MC | April 2009 | Recruiting | June 2008 |
Phase 2 Study of ABT-869 in Subjects With Advanced Renal Cell Carcinoma Who Have Previously Received Treatment With Sunitinib | 53 | Open label, NR | April 2009 | Active, not recruiting | August 2007 |
Phase 2 Study of Oxaliplatin, Fluorouracil, Leucovorin and ABT-869 or Bevacizumab as Second-Line Therapy in Treating Patients With Locally Recurrent or Metastatic Colorectal Cancer | 0 | Single center | October 2008 | Not yet recruiting | October 2008 |
Phase 1 Pharmacokinetic Study To Evaluate Effect of Food and Diurnal Variation on ABT-869 | 12 | Single center | March 2009 | Recruiting | February 2009 |